Saturday 10 October 2026
Night EditionRSS
ZOTPAPER

News without the noise

ZOTPAPER
Business

Teva wins FDA approval for monthly schizophrenia injection Weltruza

Second long-acting antipsychotic from Teva-Medincell partnership, launch expected in weeks

By LineZotpaper
Published
Read Time1 min
Teva Pharmaceutical Industries announced Friday that the U.S. Food and Drug Administration has approved Weltruza, a once-monthly injectable formulation of the antipsychotic olanzapine for adults with schizophrenia. The Israel-based company expects to launch the drug in the United States in the coming weeks.

Weltruza is the second product to emerge from Teva's partnership with French biotech company Medincell, following Uzedy, a long-acting injectable form of risperidone that received FDA approval in 2023. The new drug uses Medincell's proprietary long-acting injectable technology, designed to release medication over extended periods. According to Teva, the formulation may help address treatment-adherence challenges often seen in schizophrenia and other chronic psychiatric illnesses, where patients may stop taking daily oral medication.

Under the collaboration agreement, Medincell may be eligible for up to $112 million in additional development and commercial milestone payments, as well as royalties on sales of Weltruza. Shares of Teva rose 2% in Tel Aviv trading following the announcement. Medincell shares were suspended at the company's request ahead of the news.

§

Analysis

Why This Matters

  • Provides a new monthly injection option for schizophrenia patients, potentially improving adherence compared to daily oral antipsychotics.
  • Strengthens Teva's psychiatric portfolio and deepens its collaboration with Medincell.
  • Reflects the broader pharmaceutical industry trend toward long-acting injectable formulations for chronic mental health conditions.

Background

Schizophrenia is a chronic psychiatric disorder that often requires long-term medication. Adherence to daily oral antipsychotics can be poor, leading to relapse and hospitalization. Long-acting injectable formulations have been developed to address this challenge by delivering medication over weeks or months, reducing the burden of daily pill-taking.

Key Perspectives

Patients and clinicians: A once-monthly injection of olanzapine may offer a more convenient option and help maintain consistent treatment, potentially reducing relapse rates. Teva leadership: The company advances its pipeline of differentiated central nervous system therapies, building on the earlier approval of Uzedy. Market observers: Investors responded positively to the approval, with Teva shares gaining 2% in Tel Aviv, signaling confidence in the drug's commercial prospects.

What to Watch

  • Prescription volume and market adoption of Weltruza in the U.S. post-launch.
  • Achievement of milestone payments to Medincell as sales targets are met.
  • Potential competition from other long-acting antipsychotic products, including those based on olanzapine.

Sources

Zotpaper

Written by software from the reporting listed above, scored by an automated standards desk, and published without a person reading it first. If something here is wrong, tell the editor and it will be put right.

How we workSubscribe